Eliminate Coronary Artery Disease "ECAD"


Phase 2 Results N/A

Trial Description

The purpose of this study is to determine whether pharmacologic lowering of low density lipoprotein cholesterol (LDL), initiated in healthy young to middle aged adults can eliminate or markedly reduce the composite endpoint of incident all cause mortality, myocardial infarction, stroke or coronary revascularization.



  • Atorvastatin (LipitorĀ®)Drug
    Other Names: Lipitor
    Intervention Desc: 20 mg of atorvastatin daily
    ARM 1: Kind: Experimental
    Label: Atorvastatin
    Description: Atorvastatin(Lipitor) in addition to the usual guideline based care

Trial Design

  • Allocation: Randomized
  • Masking: Open Label
  • Purpose: Prevention
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment


Type Measure Time Frame Safety Issue
Primary Time to first occurrence of myocardial infarction, revascularization, stroke or death from any cause in the follow up period Up to 10 years No